Educational guide
Bronchogen Overview, Dosing & Safety | Peptide Database
Bronchogen (AEDL) AEDL Tetrapeptide | Bronchial Bioregulator Community Research Join others researching Bronchogen — share findings, ask questions, and learn from real experiences Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Bronchogen (AEDL)
AEDL Tetrapeptide | Bronchial Bioregulator
Community Research
Join others researching Bronchogen — share findings, ask questions, and learn from real experiences
Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides, Bronchogen penetrates cell nuclei to influence gene expression related to respiratory tissue maintenance and repair.
Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows efficient cellular uptake and tissue-specific targeting to bronchial structures.
Molecular Data
Alanine
Position 1
Glutamic Acid
Position 2
Aspartic Acid
Position 3
Leucine
Position 4
Research Indications
Supports bronchial tissue through gene expression regulation.
Helps maintain respiratory epithelium health.
Regulates protein synthesis in lung tissue.
Addresses age-related changes in bronchial tissue.
Modulates gene expression in respiratory cells.
Dosing Protocols
Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles.
Standard protocol
10-20 mg
Daily for 10-20 days
Oral capsules
Maintenance
10 mg
2-3 cycles yearly
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
Generally well-tolerated
Minimal side effects reported
Stop Signs - Discontinue if:
Allergic reactions
Unusual respiratory symptoms
Contraindications
Active respiratory emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Quality Checklist
Good Signs
White powder or capsules
Clear solution if reconstituted
Proper packaging and labeling
Warning Signs
Unknown source or purity
Bad Signs
Discoloration
Unusual odor
Damaged packaging
Frequently Asked Questions
How do Khavinson bioregulator peptides work if their half-life is just minutes?
Bronchogen's tetrapeptide structure allows it to penetrate cell nuclei directly and modulate gene expression epigenetically. Despite its short circulating half-life, it triggers lasting changes in DNA regulation and protein synthesis in bronchial tissue. These epigenetic changes persist long after the peptide itself clears circulation.
What respiratory benefits have been proven in human trials for Bronchogen?
Clinical evidence on Bronchogen specifically is limited. Most research comes from Russian sources showing improvements in respiratory function when combined with other Khavinson peptides. Clear human efficacy data from double-blind trials doesn't exist in English-language literature.
Can I combine Bronchogen with other respiratory support supplements?
Yes. Bronchogen's epigenetic mechanism complements other approaches. It pairs well with standard respiratory support compounds, though no specific clinical data on combinations exists. Other Khavinson peptides like Chonluten target related respiratory systems synergistically.
How long before I notice respiratory improvements on Bronchogen?
Bronchogen works through gene expression changes that occur during the 10-20 day cycle. Noticeable respiratory improvements typically emerge weeks to months after cycles complete as the epigenetic changes take effect. Results improve with repeated 2-3 cycles yearly for cumulative benefits.
References
Comprehensive review of bioregulator peptides including respiratory bioregulators.
Tetrapeptides derived from bronchial tissue regulate protein synthesis in respiratory cells.
Short peptides support bronchopulmonary system through epigenetic mechanisms.
Related Peptides
Related respiratory bioregulators; complementary mechanisms.
Often combined in comprehensive anti-aging Khavinson protocols.
Both have immune-modulating properties; different tissue targets.
Part of Khavinson bioregulator family; targets different tissue.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.